| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K64610608 | CTRPv2 | pan-cancer | AAC | -0.13 | 0.009 |
| mRNA | Bortezomib | gCSI | pan-cancer | AAC | 0.17 | 0.01 |
| mRNA | Methotrexate | GDSC1000 | pan-cancer | AAC | -0.081 | 0.01 |
| mRNA | BRD-K09344309 | CTRPv2 | pan-cancer | AAC | -0.24 | 0.01 |
| mRNA | BRD-K27986637 | CTRPv2 | pan-cancer | AAC | 0.24 | 0.01 |
| mRNA | YM201636 | GDSC1000 | pan-cancer | AAC | -0.083 | 0.01 |
| mRNA | Bexarotene | GDSC1000 | pan-cancer | AAC | 0.096 | 0.01 |
| mRNA | etoposide | GDSC1000 | pan-cancer | AAC | -0.093 | 0.01 |
| mRNA | BMS-754807 | GDSC1000 | pan-cancer | AAC | -0.089 | 0.01 |
| mRNA | temsirolimus | GDSC1000 | pan-cancer | AAC | 0.089 | 0.01 |